Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Epidemiology and clinical manifestations of Cushing's syndrome

Lynnette K Nieman, MD
Section Editor
André Lacroix, MD
Deputy Editor
Kathryn A Martin, MD


The symptoms and signs of Cushing's syndrome result directly from chronic exposure to excess glucocorticoid. Establishing the diagnosis is often difficult because few of the symptoms or signs are pathognomonic of the syndrome in isolation. There is a large spectrum of manifestations from subclinical to overt syndrome, depending on duration and intensity of excess steroid production. Furthermore, some of them (such as obesity, hypertension, and glucose intolerance) are common in individuals who do not have adrenal hyperfunction. An important clinical clue to the presence of glucocorticoid excess is the simultaneous development and increasing severity of several of these symptoms.

The major manifestations of Cushing's syndrome will be reviewed here. The diagnosis and treatment of this disorder and Cushing's syndrome during pregnancy are discussed separately. (See "Establishing the diagnosis of Cushing's syndrome" and "Establishing the cause of Cushing's syndrome" and "Overview of the treatment of Cushing's syndrome" and "Cushing's syndrome in pregnancy".)


Estimates of the incidence of Cushing's syndrome are imprecise and likely underestimate the incidence of iatrogenic Cushing's syndrome, undiagnosed mild hypercortisolism, and the ectopic corticotropin (ACTH) syndrome.

Iatrogenic Cushing's syndrome More than 10 million Americans receive pharmacologic doses of glucocorticoids each year. Therefore, iatrogenic Cushing's syndrome must be more common than any other cause but is seldom reported. (See "Major side effects of systemic glucocorticoids", section on 'Cushingoid appearance and weight gain'.)

Cushing's disease Pituitary ACTH-dependent Cushing's syndrome is five to six times more common than Cushing's syndrome caused by benign and malignant adrenal tumors combined [1]. Thus, the incidence of Cushing's disease may be 5 to 25 per million per year. However, the reported incidence was much lower (1.2 to 2.4 per million per year) in one population-based study [2,3]. In a United States study, the incidence was higher than previously reported in European studies as it was found to affect 6.2 to 7.6 per million person-years [4]. (See "Causes and pathophysiology of Cushing's syndrome", section on 'Cushing's disease'.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Dec 2016. | This topic last updated: Wed Jan 11 00:00:00 GMT 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Carpenter PC. Diagnostic evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am 1988; 17:445.
  2. Lindholm J, Juul S, Jørgensen JO, et al. Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001; 86:117.
  3. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40:479.
  4. Broder MS, Neary MP, Chang E, et al. Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States. Pituitary 2015; 18:283.
  5. Orth DN. Ectopic hormone production. In: Endocrinology and metabolism, Felig P, Baxter JD, Broadus AE, Frohman LA (Eds), McGraw-Hill, New York 1987. p.1692.
  6. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24:4539.
  7. Ross NS. Epidemiology of Cushing's syndrome and subclinical disease. Endocrinol Metab Clin North Am 1994; 23:539.
  8. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84:440.
  9. James BC, Aschebrook-Kilfoy B, Cipriani N, et al. The Incidence and Survival of Rare Cancers of the Thyroid, Parathyroid, Adrenal, and Pancreas. Ann Surg Oncol 2016; 23:424.
  10. Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 1966; 41:572.
  11. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322:1195.
  12. Kasperlik-Załuska AA, Migdalska BM, Zgliczyński S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995; 75:2587.
  13. Batista DL, Oldfield EH, Keil MF, Stratakis CA. Postoperative testing to predict recurrent Cushing disease in children. J Clin Endocrinol Metab 2009; 94:2757.
  14. Joshi SM, Hewitt RJ, Storr HL, et al. Cushing's disease in children and adolescents: 20 years of experience in a single neurosurgical center. Neurosurgery 2005; 57:281.
  15. Storr HL, Isidori AM, Monson JP, et al. Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis. J Clin Endocrinol Metab 2004; 89:3818.
  16. Magiakou MA, Mastorakos G, Oldfield EH, et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 1994; 331:629.
  17. Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981; 71:855.
  18. Neville AM, Symington T. Bilateral adrenocortical hyperplasia in children with Cushing's syndrome. J Pathol 1972; 107:95.
  19. Howlett TA, Rees LH, Besser GM. Cushing's syndrome. Clin Endocrinol Metab 1985; 14:911.
  20. Katayama M, Nomura K, Ujihara M, et al. Age-dependent decline in cortisol levels and clinical manifestations in patients with ACTH-independent Cushing's syndrome. Clin Endocrinol (Oxf) 1998; 49:311.
  21. Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002; 87:998.
  22. Ross EJ, Linch DC. Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2:646.
  23. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526.
  24. Nieman LK. Cushing's syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol 2015; 173:M33.
  25. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 1998; 83:3083.
  26. Penezić Z, Zarković M, Vujović S, et al. Gonadotropin pulsatility in Cushing's syndrome compared with polycystic ovary syndrome. Gynecol Endocrinol 2005; 20:150.
  27. Kaltsas GA, Korbonits M, Isidori AM, et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome? Clin Endocrinol (Oxf) 2000; 53:493.
  28. Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 1974; 39:340.
  29. Hammond GL, Ruokonen A, Kontturi M, et al. The simultaneous radioimmunoassay of seven steroids in human spermatic and peripheral venous blood. J Clin Endocrinol Metab 1977; 45:16.
  30. Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240:324.
  31. D'Agata R, Malozowski S, Barkan A, et al. Steroid biosynthesis in human adrenal tumors. Horm Metab Res 1987; 19:386.
  32. Gröndal S, Eriksson B, Hagenäs L, et al. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol (Copenh) 1990; 122:656.
  33. Starkman MN. Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol Metab Clin North Am 2013; 42:477.
  34. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19:647.
  35. Rosenberg EM, Hahn TJ, Orth DN, et al. ACTH-secreting medullary carcinoma of the thyroid presenting a severe idiopathic osteoporosis and senile purpura: report of a case and review of the literature. J Clin Endocrinol Metab 1978; 47:255.
  36. Urbanic RC, George JM. Cushing's disease--18 years' experience. Medicine (Baltimore) 1981; 60:14.
  37. Ferguson JK, Donald RA, Weston TS, Espiner EA. Skin thickness in patients with acromegaly and Cushing's syndrome and response to treatment. Clin Endocrinol (Oxf) 1983; 18:347.
  38. Mountjoy KG. The human melanocyte stimulating hormone receptor has evolved to become "super-sensitive" to melanocortin peptides. Mol Cell Endocrinol 1994; 102:R7.
  39. Giordano C, Guarnotta V, Pivonello R, et al. Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? Eur J Endocrinol 2014; 170:311.
  40. Leibowitz G, Tsur A, Chayen SD, et al. Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf) 1996; 44:717.
  41. Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab 2003; 88:5808.
  42. Mullan K, Black N, Thiraviaraj A, et al. Is there value in routine screening for Cushing's syndrome in patients with diabetes? J Clin Endocrinol Metab 2010; 95:2262.
  43. Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 2010; 95:2736.
  44. Koh JM, Kim JY, Chung YE, et al. Increased urinary albumin excretion in Cushing's syndrome: remission after correction of hypercortisolaemia. Clin Endocrinol (Oxf) 2000; 52:349.
  45. Wajchenberg BL, Bosco A, Marone MM, et al. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab 1995; 80:2791.
  46. Koch CA, Doppman JL, Watson JC, et al. Spinal epidural lipomatosis in a patient with the ectopic corticotropin syndrome. N Engl J Med 1999; 341:1399.
  47. Davies JH, Storr HL, Davies K, et al. Final adult height and body mass index after cure of paediatric Cushing's disease. Clin Endocrinol (Oxf) 2005; 62:466.
  48. PLOTZ CM, KNOWLTON AI, RAGAN C. The natural history of Cushing's syndrome. Am J Med 1952; 13:597.
  49. Panzer SW, Patrinely JR, Wilson HK. Exophthalmos and iatrogenic Cushing's syndrome. Ophthal Plast Reconstr Surg 1994; 10:278.
  50. Bodelier AG, Groeneveld W, van der Linden AN, Haak HR. Symptomatic epidural lipomatosis in ectopic Cushing's syndrome. Eur J Endocrinol 2004; 151:765.
  51. Kola B, Christ-Crain M, Lolli F, et al. Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab 2008; 93:4969.
  52. Tomlinson JW, Draper N, Mackie J, et al. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab 2002; 87:57.
  53. Weise M, Abad V, Considine RV, et al. Leptin secretion in Cushing's syndrome: preservation of diurnal rhythm and absent response to corticotropin-releasing hormone. J Clin Endocrinol Metab 1999; 84:2075.
  54. Schafroth U, Godang K, Ueland T, et al. Leptin levels in relation to body composition and insulin concentration in patients with endogenous Cushing's syndrome compared to controls matched for body mass index. J Endocrinol Invest 2000; 23:349.
  55. Shipley JE, Schteingart DE, Tandon R, Starkman MN. Sleep architecture and sleep apnea in patients with Cushing's disease. Sleep 1992; 15:514.
  56. Rosenow F, McCarthy V, Caruso AC. Sleep apnoea in endocrine diseases. J Sleep Res 1998; 7:3.
  57. Neary NM, Booker OJ, Abel BS, et al. Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. J Clin Endocrinol Metab 2013; 98:2045.
  58. Mancini T, Kola B, Mantero F, et al. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004; 61:768.
  59. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84:2664.
  60. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88:2527.
  61. Whitworth JA. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int Suppl 1992; 37:S34.
  62. Saruta T, Suzuki H, Handa M, et al. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986; 62:275.
  63. Pirpiris M, Sudhir K, Yeung S, et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19:567.
  64. Isidori AM, Graziadio C, Paragliola RM, et al. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens 2015; 33:44.
  65. Ulick S, Wang JZ, Blumenfeld JD, Pickering TG. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1992; 74:963.
  66. Stewart PM, Walker BR, Holder G, et al. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1995; 80:3617.
  67. Takagi S, Tanabe A, Tsuiki M, et al. Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal Cushing's syndrome. Endocr J 2009; 56:1009.
  68. Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2002; 970:134.
  69. CHRISTY NP, LARAGH JH. Pathogenesis of hypokalemic alkalosis in Cushing's syndrome. N Engl J Med 1961; 265:1083.
  70. Sjöberg HE, Blombäck M, Granberg PO. Thromboembolic complications, heparin treatment in increase in coagulation factors in Cushing's syndrome. Acta Med Scand 1976; 199:95.
  71. Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002; 87:3662.
  72. van der Pas R, Leebeek FW, Hofland LJ, et al. Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 2013; 78:481.
  73. Isidori AM, Minnetti M, Sbardella E, et al. Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol 2015; 173:R101.
  74. Van Zaane B, Nur E, Squizzato A, et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 2009; 94:2743.
  75. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5:692.
  76. Stuijver DJ, van Zaane B, Feelders RA, et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab 2011; 96:3525.
  77. Terzolo M, Allasino B, Bosio S, et al. Hyperhomocysteinemia in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:3745.
  78. Ross EJ, Marshall-Jones P, Friedman M. Cushing's syndrome: diagnostic criteria. Q J Med 1966; 35:149.
  79. Gonzalez-Campoy JM, Romero JC, Knox FG. Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems. Kidney Int 1989; 35:767.
  80. Shibusawa N, Yamada M, Hashida T, et al. Dilated cardiomyopathy as a presenting feature of Cushing's syndrome. Intern Med 2013; 52:1067.
  81. Frustaci A, Letizia C, Verardo R, et al. Atrogin-1 Pathway Activation in Cushing Syndrome Cardiomyopathy. J Am Coll Cardiol 2016; 67:116.
  82. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002; 87:4872.
  83. Debono M, Bradburn M, Bull M, et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 2014; 99:4462.
  84. Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2014; 2:396.
  85. Ferrando AA, Stuart CA, Sheffield-Moore M, Wolfe RR. Inactivity amplifies the catabolic response of skeletal muscle to cortisol. J Clin Endocrinol Metab 1999; 84:3515.
  86. Alwani RA, Schmit Jongbloed LW, de Jong FH, et al. Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests. Eur J Endocrinol 2014; 170:477.
  87. Pecori Giraldi F, Pivonello R, Ambrogio AG, et al. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) 2007; 66:251.
  88. Adler RA, Rosen CJ. Glucocorticoids and osteoporosis. Endocrinol Metab Clin North Am 1994; 23:641.
  89. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112:352.
  90. Soffer LJ, Iannaccone A, Gabrilove JL. Cushing's syndrome: a study of fifty patients. Am J Med 1961; 30:129.
  91. Tauchmanovà L, Pivonello R, Di Somma C, et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 2006; 91:1779.
  92. Kaplan FS, Leone VJ, Fallon MD, et al. Multiple pathologic fractures of the appendicular skeleton in a patient with Cushing's disease. Clin Orthop Relat Res 1987; :171.
  93. Felson DT, Anderson JJ. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet 1987; 1:902.
  94. Koch CA, Tsigos C, Patronas NJ, Papanicolaou DA. Cushing's disease presenting with avascular necrosis of the hip: an orthopedic emergency. J Clin Endocrinol Metab 1999; 84:3010.
  95. Poonuru S, Findling JW, Shaker JL. Lower extremity insufficiency fractures: an underappreciated manifestation of endogenous Cushing's syndrome. Osteoporos Int 2016; 27:3645.
  96. LAAKE H. The action of corticosteroids on the renal reabsorption of calcium. Acta Endocrinol (Copenh) 1960; 34:60.
  97. Kristo C, Jemtland R, Ueland T, et al. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol 2006; 154:109.
  98. Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf) 1992; 36:229.
  99. Tóth M, Grossman A. Glucocorticoid-induced osteoporosis: lessons from Cushing's syndrome. Clin Endocrinol (Oxf) 2013; 79:1.
  100. Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J Bone Miner Res 2011; 26:1816.
  101. Haskett RF. Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry 1985; 142:911.
  102. Kelly WF. Psychiatric aspects of Cushing's syndrome. QJM 1996; 89:543.
  103. Loosen PT, Chambliss B, DeBold CR, et al. Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry 1992; 25:192.
  104. Dorn LD, Burgess ES, Dubbert B, et al. Psychopathology in patients with endogenous Cushing's syndrome: 'atypical' or melancholic features. Clin Endocrinol (Oxf) 1995; 43:433.
  106. Devoe DJ, Miller WL, Conte FA, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997; 82:3196.
  107. Dorn LD, Burgess ES, Friedman TC, et al. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997; 82:912.
  108. Kelly WF, Kelly MJ, Faragher B. A prospective study of psychiatric and psychological aspects of Cushing's syndrome. Clin Endocrinol (Oxf) 1996; 45:715.
  109. Heald AH, Ghosh S, Bray S, et al. Long-term negative impact on quality of life in patients with successfully treated Cushing's disease. Clin Endocrinol (Oxf) 2004; 61:458.
  110. Tiemensma J, Biermasz NR, Middelkoop HA, et al. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease. J Clin Endocrinol Metab 2010; 95:E129.
  111. Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol Psychiatry 1992; 32:756.
  112. Forget H, Lacroix A, Somma M, Cohen H. Cognitive decline in patients with Cushing's syndrome. J Int Neuropsychol Soc 2000; 6:20.
  113. Starkman MN, Schteingart DE, Schork MA. Correlation of bedside cognitive and neuropsychological tests in patients with Cushing's syndrome. Psychosomatics 1986; 27:508.
  114. Bourdeau I, Bard C, Noël B, et al. Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 2002; 87:1949.
  115. Resmini E, Santos A, Gómez-Anson B, et al. Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:663.
  116. Starkman MN, Giordani B, Gebarski SS, Schteingart DE. Improvement in learning associated with increase in hippocampal formation volume. Biol Psychiatry 2003; 53:233.
  117. Tiemensma J, Kokshoorn NE, Biermasz NR, et al. Subtle cognitive impairments in patients with long-term cure of Cushing's disease. J Clin Endocrinol Metab 2010; 95:2699.
  118. Merke DP, Giedd JN, Keil MF, et al. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin Endocrinol Metab 2005; 90:2531.
  119. Dekkers OM, Horváth-Puhó E, Jørgensen JO, et al. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J Clin Endocrinol Metab 2013; 98:2277.
  120. Hanson JA, Sohaib SA, Newell-Price J, et al. Computed tomography appearance of the thymus and anterior mediastinum in active Cushing's syndrome. J Clin Endocrinol Metab 1999; 84:602.
  121. Ntali G, Asimakopoulou A, Siamatras T, et al. Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 2013; 169:715.
  122. Graham BS, Tucker WS Jr. Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med 1984; 101:334.
  123. Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 2000; 85:42.
  124. Kronfol Z, Starkman M, Schteingart DE, et al. Immune regulation in Cushing's syndrome: relationship to hypothalamic-pituitary-adrenal axis hormones. Psychoneuroendocrinology 1996; 21:599.
  125. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283.
  126. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270:286.
  127. Jilma B, Stohlawetz P, Pernerstorfer T, et al. Glucocorticoids dose-dependently increase plasma levels of granulocyte colony stimulating factor in man. J Clin Endocrinol Metab 1998; 83:1037.
  128. Khaw KW, Jalaludin MY, Suhaimi H, et al. Endogenous Cushing syndrome from an ectopic adrenocorticotropic hormone production as a rare cause of ocular hypertension. J AAPOS 2010; 14:356.
  129. Huschle OK, Jonas JB, Koniszewski G, et al. [Glaucoma in central hypothalamic-hypophyseal Cushing syndrome]. Fortschr Ophthalmol 1990; 87:453.
  130. Jonas JB, Huschle O, Koniszewski G, et al. Intraocular pressure in patients with Cushing's disease. Graefes Arch Clin Exp Ophthalmol 1990; 228:407.
  131. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002; 47:431.
  132. Clayton RN, Jones PW, Reulen RC, et al. Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 2016; 4:569.
  133. Graversen D, Vestergaard P, Stochholm K, et al. Mortality in Cushing's syndrome: a systematic review and meta-analysis. Eur J Intern Med 2012; 23:278.